KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Investing Activities (2016 - 2022)

Historic Cash from Investing Activities for TherapeuticsMD (TXMD) over the last 12 years, with Q4 2022 value amounting to -$74000.0.

  • TherapeuticsMD's Cash from Investing Activities rose 9511.23% to -$74000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was -$355000.0, marking a year-over-year increase of 8403.06%. This contributed to the annual value of -$355000.0 for FY2022, which is 8403.06% up from last year.
  • Per TherapeuticsMD's latest filing, its Cash from Investing Activities stood at -$74000.0 for Q4 2022, which was up 9511.23% from $7000.0 recorded in Q3 2022.
  • TherapeuticsMD's 5-year Cash from Investing Activities high stood at $7000.0 for Q3 2022, and its period low was -$20.7 million during Q4 2019.
  • Its 5-year average for Cash from Investing Activities is -$2.5 million, with a median of -$418500.0 in 2020.
  • Per our database at Business Quant, TherapeuticsMD's Cash from Investing Activities tumbled by 2807703.55% in 2018 and then surged by 10384.62% in 2022.
  • TherapeuticsMD's Cash from Investing Activities (Quarter) stood at -$671171.0 in 2018, then tumbled by 2986.19% to -$20.7 million in 2019, then skyrocketed by 97.62% to -$494000.0 in 2020, then plummeted by 206.48% to -$1.5 million in 2021, then soared by 95.11% to -$74000.0 in 2022.
  • Its Cash from Investing Activities stands at -$74000.0 for Q4 2022, versus $7000.0 for Q3 2022 and -$76000.0 for Q2 2022.